Navigation Links
Cipralex demonstrates superiority to duloxetine for acute treatment,of depression in new study

COPENHAGEN, June 4, 2007-A new study published today in the journal Current Medical Research and Opinion showed that Cipralex® (escitalopram) was superior to Cymbalta® (duloxetine) in the acute treatment of patients with major depressive disorder (MDD) and was at least as efficacious in long-term treatment. The study directly compared Cipralex® (an allosteric serotonin reuptake inhibitor - ASRI) to duloxetine (a serotonin and noradrenaline reuptake inhibitor - SNRI) and also demonstrated that Cipralex® was better tolerated, with fewer patients discontinuing treatment with Cipralex® due to adverse events compared to duloxetine.

Depression is a serious illness that results in significant disability and is associated with both increased morbidity and the risk of suicide. Affecting around 121 million people globally, the World Health Organization lists depression as the leading cause of disability worldwide.

"Cipralex® is an effective and well-tolerated drug for the treatment of depression and a wide range of anxiety disorders," said Senior Vice President Anders Gersel Pedersen, Head of Development at Lundbeck. "These new data provide further evidence of the strong efficacy and tolerability profile of Cipralex® compared to other antidepressants in the treatment of depression."

About the clinical study The study was designed to look at the efficacy and tolerability of Cipralex® compared to duloxetine in patients with moderate to severe MDD over 24 weeks, with a secondary endpoint at eight weeks (acute treatment).

The double-blind, fixed-dose, comparative study included 294 patients with MDD from 35 centres in nine countries. Patients were randomised to either Cipralex® (n=143) or duloxetine (n=151), at dosing regimens currently recommended in the package inserts in participating countries (Cipralex® 20mg, duloxetine 60mg).

Patients were evalu ated using the MADRS rating scale from baseline to week 24. Efficacy and tolerability were assessed at baseline and after 1, 2, 4, 8, 12, 16, 20 and 24 weeks; a safety follow-up visit was performed at 28 weeks. The 24-week study found that:

* Patients taking Cipralex® demonstrated significantly greater improvement in depression symptoms at week eight (acute treatment) than patients taking duloxetine. This superiority was evident after the first week of treatment and was maintained at all time points until week 16 (p<0.05)

* Cipralex® was at least as effective as duloxetine at 24 weeks of treatment, the primary endpoint of the study (p=0.055, Cipralex® being numerically better than duloxetine)

* Patients treated with Cipralex® showed significantly better functioning in their work, family and social life at week eight and week 24, compared to duloxetine

* Cipralex® was better tolerated than duloxetine. Significantly more duloxetine patients withdrew from the study due to adverse events than those treated with Cipralex® (17 percent versus nine percent respectively)

* A post-hoc analysis of the study revealed that 68.8 percent of patients had an early onset of response with Cipralex® compared to only 54.8 percent of duloxetine-treated patients

About depression Depression is a very common, debilitating illness affecting around 121 million people worldwide. The symptoms of depression can be chronic or recurrent, and impact patients both mentally and physically. Depression has a significant impact on patient quality of life and imposes a considerable burden on society, yet it is still underrecognised and undertreated with less than 25 percent of those affected having access to effective treatment.

Symptoms include feelings of hopelessness, sadness, guilt, loss of interest in activities, decreased energy, poor concentration, persistent physical symptoms such as headache and digestive disorders, and in more severe cases, suicidal thoughts and suicide attempts.

The content of this release will have no influence on the Lundbeck Group's financial result for 2007.

Lundbeck contacts

Investors: Media: Jacob Tolstrup Caroline Broge Investor Relations Manager, Media Relations Manager North America +45 36 43 26 38 +1 201 350 0187

________________________

Release no. 276 - 4 June 2007

About Lundbeck H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approx. 5300 globally. For more information, please visit www.lundbeck.com.


'"/>




Related medicine technology :

1. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
2. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
3. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
4. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
5. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
6. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... 2017  Cellect Biotechnology Ltd. (NASDAQ: APOP ... the functional selection of stem cells, today provided a ... quarter ended March 31 st , 2017. ... the first quarter of 2017," said Dr. Shai Yarkoni, ... the treatment of the first blood cancer patient in ...
(Date:5/24/2017)... 24, 2017  ivWatch LLC today announced the ... Board to enable seamless integration of ivWatch,s groundbreaking ... infusion pumps and other devices. By integrating ivWatch ... to help health care customers deliver a higher ... to IV therapy. "The ivWatch OEM ...
(Date:5/22/2017)... , May 22, 2017  As the ... a whole continue to make the revolutionary shift ... increasingly important for ensuring positive patient outcomes and ... stakeholders are shifting focus away from clinical trials ... effects of long-term specialty drug therapy utilization in ...
Breaking Medicine Technology:
(Date:6/22/2017)... ... June 22, 2017 , ... Plastic Surgery Associates is ... Top Doctor for 2017. Each year, research and information firm, Castle Connolly, releases their ... title in 2015, this marks the 3rd time that Dr. Canales has ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... grant from the American Heart Association (AHA) to launch a Rheumatic Heart Disease ... the prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged ...
(Date:6/22/2017)... ... June 22, 2017 , ... Vighter, a premier ... received certification for ANSI/ASIS PSC.1-2012. The company’s work in countries throughout Southwest Asia, ... of law has been degraded. The PSC.1 standard was created to protect fundamental ...
(Date:6/20/2017)... Tennessee (PRWEB) , ... June 20, 2017 , ... ... care services, announced today that Claritas Capital, a Nashville-based private equity firm, has ... accelerate our expansion plans for some time, and Claritas Capital offers the smart ...
(Date:6/20/2017)... ... 2017 , ... After months of negotiations, FaceCradle USA is proud to announce the debut of ... , “Introducing our product on QVC is something we all worked hard to achieve for ... more than 90 million homes in the United States,” said FaceCradle USA President Dylan Doherty. ...
Breaking Medicine News(10 mins):